Profile data is unavailable for this security.
About the company
Destiny Pharma plc is a clinical-stage biotechnology company. The Company is focused on the development and commercialization of novel medicines that can prevent life-threatening infections. The Company's drug development pipeline includes two late stage assets, NTCD-M3, a microbiome-based biotherapeutic for the prevention of C.difficile infection (CDI) recurrence, which is the principal cause of hospital acquired infection in the United States, and XF-73 nasal gel, a proprietary drug targeting the prevention of postsurgical staphylococcal hospital infections including methicillin-resistant Staphylococcus aureus (MRSA), and has the potential to reduce hospitalization stay, accelerate recovery and rehabilitation and improve quality of life for patients undergoing vital surgeries. The Company’s earlier stage pipeline is focused on other indications including two, separate dermal programs incorporating its XF platform.
- Revenue in GBP (TTM)0.00
- Net income in GBP-5.66m
- Incorporated1996
- Employees19.00
- LocationDestiny Pharma PLCSussex Innovation CentreScience Park Square, FalmerBRIGHTON BN1 9SBUnited KingdomGBR
- Phone+44 127 370 4440
- Fax+44 127 370 4414
- Websitehttps://www.destinypharma.com/